Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement of active site side chains

Molecular Pharmacology

Volumn 80, Issue 6, 2011, Pages 1047-1055

  Shah, Manish B ^a   Pascual, Jaime ^a   Zhang, Qinghai ^b   Stout, C David ^b   Halpert, James R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 NITROBENZYL)PYRIDINE; 4 BENZYLPYRIDINE; CYTOCHROME P450 2B6; HISTIDINE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CONFORMATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; SINGLE NUCLEOTIDE POLYMORPHISM; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ARYL HYDROCARBON HYDROXYLASES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEIN BINDING; PROTEIN CONFORMATION; PYRIDINES;

EID: 81555222817     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.074427     Document Type: Article

References (40)

1. Bumpus NN and Hollenberg PF (2010) Cross-linking of human cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: identification of a potential site of interaction. J Inorg Biochem 104:485-488.
2. Collaborative Computational Project and Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763.
3. Davis IW, Murray LW, Richardson JS, and Richardson DC (2004) MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 32:W615-W619. (Pubitemid 38997409)
4. DeLano WL (2002) The PyMOL Molecular Graphics System (MacPyMOL edition), DeLano Scientific, Palo Alto, CA.
5. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, and Zanger UM (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547-558. (Pubitemid 46947859)
6. Domanski TL and Halpert JR (2001a) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117-137. (Pubitemid 32536998)
7. Domanski TL, He YA, Harlow GR, and Halpert JR (2000) Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J Pharmacol Exp Ther 293:585-591. (Pubitemid 30244111)
8. Domanski TL, He YQ, Scott EE, Wang Q, and Halpert JR (2001b) The role of cytochrome 2B1 substrate recognition site residues 115, 294, 297, 298, and 362 in the oxidation of steroids and 7-alkoxycoumarins. Arch Biochem Biophys 394:21-28. (Pubitemid 32948280)
9. Domanski TL, Liu J, Harlow GR, and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and α-naphthoflavone stimulation. Arch Biochem Biophys 350:223-232. (Pubitemid 28368647)
10. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. (Pubitemid 41742764)
11. Gay SC, Roberts AG, and Halpert JR (2010a) Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. Future Med Chem 2:1451-1468.
12. Gay SC, Roberts AG, Maekawa K, Talakad JC, Hong WX, Zhang Q, Stout CD, and Halpert JR (2010b) Structures of cytochrome P450 2B4 complexed with the anti-platelet drugs ticlopidine and clopidogrel. Biochemistry 49:8709-8720.
13. Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang JY, Huelga SC, Hong WX, et al. (2010c) Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl) imidazole at 2.0-A resolution. Mol Pharmacol 77:529-538.
14. Gay SC, Zhang H, Wilderman PR, Roberts AG, Liu T, Li S, Lin HL, Zhang Q, Woods VL Jr, Stout CD, et al. (2011) Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity. Biochemistry 50:4903-4911.
15. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206-216. (Pubitemid 30205131)
16. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402. (Pubitemid 27102356)
17. He Y, Luo Z, Klekotka PA, Burnett VL, and Halpert JR (1994) Structural determinants of cytochrome P450 2B1 specificity: evidence for five substrate recognition sites. Biochemistry 33:4419-4424. (Pubitemid 24140631)
18. Holmans PL, Shet MS, Martin-Wixtrom CA, Fisher CW, and Estabrook RW (1994) The high-level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5 and studies on their mechanism of function. Arch Biochem Biophys 312:554-565.
19. Johnson EF and Stout CD (2005) Structural diversity of human xenobioticmetabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:331-336. (Pubitemid 41540575)
20. Kleywegt GJ and Jones TA (1994) Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr 50:178-185. (Pubitemid 2054290)
21. Kobayashi Y, Strobel SM, Hopkins NE, Alworth WL, and Halpert JR (1998) Catalytic properties of an expressed cytochrome P450 2B1 from a Wistar-Kyoto rat liver cDNA library. Drug Metab Dispos 26:1026-1030. (Pubitemid 28478265)
22. Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso A, Pelkonen O, Raunio H, and Juvonen RO (2007) New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br J Pharmacol 150:932-942. (Pubitemid 46536632)
23. Kumar S, Zhao Y, Sun L, Negi SS, Halpert JR, and Muralidhara BK (2007) Rational engineering of human cytochrome P450 2B6 for enhanced expression and stability: importance of a Leu2643Phe substitution. Mol Pharmacol 72:1191-1199. (Pubitemid 350012593)
24. Leslie AG (1999) Integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 55:1696-1702.
25. Lindberg RL and Negishi M (1991) Modulation of specificity and activity in mammalian cytochrome P-450. Methods Enzymol 202:741-752.
26. Long F, Vagin AA, Young P, and Murshudov GN (2008) BALBES: a molecular-replacement pipeline. Acta Crystallogr D Biol Crystallogr 64:125-132. (Pubitemid 350308686)
27. Mitsuda M and Iwasaki M (2006) Improvement in the expression of CYP2B6 by co-expression with molecular chaperones GroES/EL in Escherichia coli. Protein Expr Purif 46:401-405.
28. Murshudov GN, Vagin AA, and Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255. (Pubitemid 27235885)
29. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
30. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68. (Pubitemid 33030143)
31. Scott EE, White MA, He YA, Johnson EF, Stout CD, and Halpert JR (2004) Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-Å resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 279:27294-27301. (Pubitemid 38812569)
32. Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, Wiley-Interscience, New York.
33. Soltis SM, Cohen AE, Deacon A, Eriksson T, Gonzá lez A, McPhillips S, Chui H, Dunten P, Hollenbeck M, Mathews I, et al. (2008) New paradigm for macromolecular crystallography experiments at SSRL: automated crystal screening and remote data collection. Acta Crystallogr D Biol Crystallogr 64:1210-1221.
34. van Aalten DM, Bywater R, Findlay JB, Hendlich M, Hooft RW, and Vriend G (1996) PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J Comput Aided Mol Des 10:255-262.
35. Wilderman PR, Shah MB, Liu T, Li S, Hsu S, Roberts AG, Goodlett DR, Zhang Q, Woods VL Jr, Stout CD, et al. (2010) Plasticity of cytochrome P450 2B4 as investigated by hydrogen-deuterium exchange mass spectrometry and x-ray crystallography. J Biol Chem 285:38602-38611.
36. Williams PA, Cosme J, Sridhar V, Johnson EF, and McRee DE (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121-131. (Pubitemid 30105441)
37. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743-759. (Pubitemid 47288975)
38. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, and Hollenberg PF (2011) Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional P450- reductase complex. J Pharmacol Exp Ther 338:803-809.
39. Zhang Q, Ma X, Ward A, Hong WX, Jaakola VP, Stevens RC, Finn MG, and Chang G (2007) Designing facial amphiphiles for the stabilization of integral membrane proteins. Angew Chem Int Ed Engl 46:7023-7025. (Pubitemid 47492227)
40. Zhao Y, Sun L, Muralidhara BK, Kumar S, White MA, Stout CD, and Halpert JR (2007) Structural and thermodynamic consequences of 1-(4-chlorophenyl) imidazole binding to cytochrome P450 2B4. Biochemistry 46:11559-11567. (Pubitemid 47585501)